Some of the facts and figures about clinical research industry are as follows:
The clinical trials industry has clear potential for strong growth in the future, driven by technological and scientific advances. This trend is complemented by the development of new trial designs, with a view to rationalizing and accelerating the drug discovery process by identifying failures at an earlier stage.
Human micro dosing clearly holds significant promise as an analytical tool. In the coming years, as research methods and technology involved in Phase 0 trials become more sophisticated, human micro dosing may be applied to a number of drugs that could potentially be administered consecutively.
Looking further into the future, the trend of combining adaptive designs with the goals of Phase II b and Phase III trials is likely to become the norm. This type of trial, described as ‘seamless adaptive’, will aim to become even more time-efficient, although it may carry higher risks for first-in-class drugs.
Phase IV trials will continue to grow at an estimated annual rate of over 20 percent. According to some estimates, companies are likely to invest over US$12 billion in this area in the course of 2007. Phase IV trials will be increasingly used to expand a drug’s indications, its geographical reach, as well as to disseminate and patients alike.
India is increasingly becoming the hub of clinical trials for all major pharma companies across the world due to its advantages of treatment naïve patient population, state of the art and yet cost effective trial sites, high percentage of English speaking Medical Professionals and timely completion of projects.
CRO’s are multiplying by the dozen and pharma companies also see that more numbers of outsourced trials are successful compared to the in-house trial